T2 Biosystms Stock Performance
| TTOO Stock | USD 2.76 0.04 1.47% |
The firm owns a Beta (Systematic Risk) of 2.01, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, T2 Biosystms will likely underperform. T2 Biosystms has an expected return of -0.45%. Please make sure to validate T2 Biosystms total risk alpha, as well as the relationship between the kurtosis and market facilitation index , to decide if T2 Biosystms performance from the past will be repeated sooner or later.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days T2 Biosystms has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in May 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return (3.27) | Five Day Return (12.62) | Year To Date Return (51.39) | Ten Year Return (100.00) | All Time Return (100.00) |
Last Split Factor 1:100 | Last Split Date 2023-10-13 |
1 | T2 BioSystems stock brace for TTOO volatility this week | 02/12/2024 |
2 | T2 Biosystems, Inc. Q4 2023 Earnings Call Transcript | 02/16/2024 |
3 | Acquisition by Brett Giffin of tradable shares of T2 Biosystms subject to Rule 16b-3 | 02/20/2024 |
4 | T2 Biosystems OrthoPediatrics Head to Head Contrast | 02/23/2024 |
5 | Exercise or conversion by Sperzel John J Iii of tradable shares of T2 Biosystms subject to Rule 16b-3 | 02/27/2024 |
6 | TTOO Stock T2 Biosystems Has Until May 20 to Regain Nasdaq Compliance | 03/12/2024 |
7 | T2 Biosystems reports high accuracy in sepsis test study | 03/18/2024 |
8 | T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates | 03/20/2024 |
9 | T2 Biosystems extends contract with Vizient | 03/28/2024 |
10 | T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity | 04/11/2024 |
11 | Acquisition by Cr Group L.p. of 17160 shares of T2 Biosystms subject to Rule 16b-3 | 04/12/2024 |
12 | Acquisition by Cr Group L.p. of 136409 shares of T2 Biosystms subject to Rule 16b-3 | 04/17/2024 |
13 | T2 Biosystems files to sell common stock, warrants | 04/22/2024 |
| Begin Period Cash Flow | 10.3 M |
TTOO |
T2 Biosystms Relative Risk vs. Return Landscape
If you would invest 422.00 in T2 Biosystms on January 26, 2024 and sell it today you would lose (146.00) from holding T2 Biosystms or give up 34.6% of portfolio value over 90 days. T2 Biosystms is currently does not generate positive expected returns and assumes 7.0041% risk (volatility on return distribution) over the 90 days horizon. In different words, 62% of stocks are less volatile than TTOO, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
T2 Biosystms Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for T2 Biosystms' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as T2 Biosystms, and traders can use it to determine the average amount a T2 Biosystms' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0646
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TTOO |
Estimated Market Risk
| 7.0 actual daily | 62 62% of assets are less volatile |
Expected Return
| -0.45 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average T2 Biosystms is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of T2 Biosystms by adding T2 Biosystms to a well-diversified portfolio.
T2 Biosystms Fundamentals Growth
TTOO Stock prices reflect investors' perceptions of the future prospects and financial health of T2 Biosystms, and T2 Biosystms fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on TTOO Stock performance.
| Return On Equity | -6.22 | ||||
| Return On Asset | -0.85 | ||||
| Operating Margin | (5.55) % | ||||
| Current Valuation | 48.8 M | ||||
| Shares Outstanding | 8.79 M | ||||
| Price To Earning | (2.04) X | ||||
| Price To Book | 14.50 X | ||||
| Price To Sales | 2.41 X | ||||
| Revenue | 7.19 M | ||||
| Gross Profit | (24.77 M) | ||||
| EBITDA | (46.29 M) | ||||
| Net Income | (50.08 M) | ||||
| Cash And Equivalents | 13.21 M | ||||
| Cash Per Share | 1.87 X | ||||
| Total Debt | 49.5 M | ||||
| Debt To Equity | 6.64 % | ||||
| Current Ratio | 1.87 X | ||||
| Book Value Per Share | (6.91) X | ||||
| Cash Flow From Operations | (48.2 M) | ||||
| Earnings Per Share | (19.19) X | ||||
| Market Capitalization | 23.92 M | ||||
| Total Asset | 34.8 M | ||||
| Retained Earnings | (584.3 M) | ||||
| Working Capital | (30.96 M) | ||||
| Current Asset | 77.78 M | ||||
| Current Liabilities | 18.54 M | ||||
About T2 Biosystms Performance
To evaluate T2 Biosystms Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when T2 Biosystms generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare TTOO Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand T2 Biosystms market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents TTOO's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 109.78 | 60.86 | |
| Return On Tangible Assets | (1.44) | (1.51) | |
| Return On Capital Employed | 2.21 | 2.32 | |
| Return On Assets | (1.44) | (1.51) | |
| Return On Equity | 1.79 | 1.88 |
Things to note about T2 Biosystms performance evaluation
Checking the ongoing alerts about T2 Biosystms for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for T2 Biosystms help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| T2 Biosystms generated a negative expected return over the last 90 days | |
| T2 Biosystms has high historical volatility and very poor performance | |
| T2 Biosystms has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 7.19 M. Net Loss for the year was (50.08 M) with loss before overhead, payroll, taxes, and interest of (24.77 M). | |
| T2 Biosystms currently holds about 13.21 M in cash with (48.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.87. | |
| T2 Biosystms has a frail financial position based on the latest SEC disclosures | |
| Latest headline from seekingalpha.com: T2 Biosystems files to sell common stock, warrants |
- Analyzing T2 Biosystms' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether T2 Biosystms' stock is overvalued or undervalued compared to its peers.
- Examining T2 Biosystms' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating T2 Biosystms' management team can have a significant impact on its success or failure. Reviewing the track record and experience of T2 Biosystms' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of T2 Biosystms' stock. These opinions can provide insight into T2 Biosystms' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for TTOO Stock analysis
When running T2 Biosystms' price analysis, check to measure T2 Biosystms' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy T2 Biosystms is operating at the current time. Most of T2 Biosystms' value examination focuses on studying past and present price action to predict the probability of T2 Biosystms' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move T2 Biosystms' price. Additionally, you may evaluate how the addition of T2 Biosystms to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
Is T2 Biosystms' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of T2 Biosystms. If investors know TTOO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about T2 Biosystms listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.19) | Revenue Per Share 2.756 | Quarterly Revenue Growth (0.69) | Return On Assets (0.85) | Return On Equity (6.22) |
The market value of T2 Biosystms is measured differently than its book value, which is the value of TTOO that is recorded on the company's balance sheet. Investors also form their own opinion of T2 Biosystms' value that differs from its market value or its book value, called intrinsic value, which is T2 Biosystms' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because T2 Biosystms' market value can be influenced by many factors that don't directly affect T2 Biosystms' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between T2 Biosystms' value and its price as these two are different measures arrived at by different means. Investors typically determine if T2 Biosystms is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, T2 Biosystms' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.